Claritev (CTEV) 10% Owner Ares Management LLC Buys $1.2M of Stock
Key Points
- Ares Management LLC, a 10% owner, added 50,000 shares of Claritev Corporation at a price of $23.53 each, boosting its total holdings to 1,913,105 shares.
- The stock closed at $23.50 on October 23, 2026, but recently traded below that at $22.65 on October 27, 2026.
- Claritev Corporation has a market cap of about $383.9 million and is set to report earnings on November 9, 2026.
Since the trade, $CTEV is down 3.6% to date (from the $23.50 close on Oct 23, 2026).
Get Claritev text alerts
We text you when insiders, Congress, analysts or big funds move on $CTEV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Claritev Corporation alert may contain errors. Disclosures
Ares Management LLC bought 50,000 shares of Claritev Corporation (NYSE: CTEV) on October 23, 2026, for about $1,176,640. This purchase raises Ares Management's total ownership in the healthcare data analytics company to 1,913,105 shares. The information comes from a Form 4 filing with the SEC.
Ares Management's recent buy increased its stake by about 2.68%. The firm is a significant investor in Claritev, which provides technology solutions to the healthcare sector. The stock closed at $23.50 on the day of the purchase.
CTEV
Claritev Corporation
Other Institutional Activity in Claritev Corporation
Several other institutional investors hold significant stakes in Claritev Corporation. H&F Corporate Investors VIII, Ltd. has 3,887,858 shares valued at about $88.1 million. Ares Management LLC, prior to the recent purchase, held 1,863,105 shares worth around $42.2 million. Arini Capital Management Ltd owns 1,534,687 shares, valued at approximately $34.8 million, while the Public Investment Fund holds 1,281,250 shares worth about $29 million. Beach Point Capital Management LP trimmed its holdings slightly, ending up with 750,599 shares worth about $17 million.
Claritev Corporation Stock Up 5.2%
As of October 27, 2026, Claritev's stock was recently trading around $22.65, which is below its closing price of $23.50 on October 23, 2026. This recent price is significantly lower than its 52-week high of $73.68 and also below its 50-day moving average of $29.98. The stock has been trading well above its 52-week low of $11.50, reflecting a 97% increase from that point.
Recent Earnings
Claritev Corporation reported trailing twelve-month revenue of approximately $994.7 million, with a year-over-year revenue growth of 6.6%. However, the company has faced challenges, posting a net margin of -28.5%. The next earnings report is set for November 9, 2026.
Insider Buying and Selling at Claritev Corporation
Before this trade, Claritev’s CEO, Travis Dalton, bought 6,450 shares on August 28, 2026, valued at about $249,664. Meanwhile, CFO Douglas Michael Garis sold 9,025 shares on September 21, 2026, for approximately $276,075.
Analysts Set New Price Targets
On August 10, 2026, Citigroup maintained a "Buy" rating on Claritev with a price target of $45.00, up from $40.00. Canaccord Genuity also maintained a "Buy" rating with a target of $43.00, increasing it from $37.00. The consensus among analysts suggests a mean price target of $46.00, indicating potential upside from current levels.
About Claritev Corporation
Claritev Corporation, based in McLean, Virginia, provides data analytics and technology-enabled solutions for cost management and revenue integrity in the healthcare industry. With a workforce of about 3,000 employees, Claritev is positioned to leverage its technology to enhance healthcare services across the United States.
Bottom Line
Investors should keep an eye on Claritev Corporation's upcoming earnings report on November 9, 2026. Ares Management's recent purchase adds to its stake in the company, which has seen varying analyst ratings and price targets. With the stock trading below its historical highs, it may present a point of interest for future movements.
Related Filing Alerts
Source: Ares Management LLC's Form 4 filing on $CTEV (Oct 23, 2026). Written by software, not financial advice. How we make alerts